Dermatology
Rosacea
Subtype-driven (erythematotelangiectatic, papulopustular, phymatous, ocular), trigger avoidance, topical + systemic therapies.
Source: BAD 2017; NICE CKS
Step 1 of ~7
info
Subtypes + Workup
Chronic inflammatory facial dermatosis. Subtypes (often overlap):
• Erythematotelangiectatic (ETR): central facial erythema + telangiectasia + flushing.
• Papulopustular (PPR): papules + pustules + erythema (looks like acne but no comedones).
• Phymatous: tissue thickening — rhinophyma (nose), gnathophyma (chin), otophyma (ears).
• Ocular: blepharitis, dry eye, conjunctival injection, keratitis (refer ophthalmology).
Triggers: sunlight, alcohol, hot drinks, spicy food, stress, exercise, temperature extremes, topical steroid (worsens).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Doxycycline (Systemic — Ocular Rosacea / Blepharitis) · Tetracycline Antibiotic — Anti-inflammatory (Ocular Rosacea / MGD)
- Dapsone · Anti-inflammatory / Antimicrobial
- Azelaic Acid 15–20% · Topical dicarboxylic acid (anti-acne / anti-rosacea)
- Metronidazole Topical · Topical Antibiotic/Antiprotozoal — Rosacea
- Ivermectin Cream (Topical) · Topical Antiparasitic — Rosacea
- Brimonidine Gel (Topical) · Alpha-2 Agonist — Rosacea Erythema
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only. Always apply local guidelines and clinical judgement.